Sign In
Buy LLY
$1,125.38
+42.15 (+3.89%)
At Close: Jun 04, 2026
Liver Disease Biotechs Dive on Eli Lilly Data
03:48pm, Wednesday, 07'th Feb 2024
MASH is an advanced liver disorder that can lead to cancer or liver failure.
Eli Lilly settles Minnesota lawsuit over insulin pricing
10:23am, Wednesday, 07'th Feb 2024
Eli Lilly has settled a lawsuit by Minnesota that accused the three largest insulin makers of deceptively raising the price of insulin, which is used to treat diabetes.
Three-Stock Lunch: Eli Lilly, Spotify and Chipotle
02:54pm, Tuesday, 06'th Feb 2024
Courtney Garcia, Payne Capital Management senior wealth advisor, joins 'Power Lunch' to discuss three stocks: Eli Lilly, Spotify and Chipotle.
Eli Lilly, Novo Nordisk Could Be First Trillion-Dollar Drug Stocks
02:48pm, Tuesday, 06'th Feb 2024
The trillion-dollar market valuation club is currently dominated by the tech sector. Saudi Aramco is the sole exception.
Healthy Returns: Novo Nordisk, Eli Lilly are tackling weight loss drug supply woes
02:13pm, Tuesday, 06'th Feb 2024
Novo Nordisk and Eli Lilly are working to increase supply of their popular weight loss drugs. Meanwhile, the implantable neurotechnology field is heating up.
Eli Lilly (LLY) Hits High After Earnings & Tesla (TSLA) Higher
02:00pm, Tuesday, 06'th Feb 2024
Eli Lilly (LLY) hits all-time high after earnings. Its 4Q adjusted EPS came in at $2.49 versus an estimated $2.50 and revenue came in at $9.35B versus an estimated $8.86B.
Compared to Estimates, Lilly (LLY) Q4 Earnings: A Look at Key Metrics
12:31pm, Tuesday, 06'th Feb 2024
While the top- and bottom-line numbers for Lilly (LLY) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare t
Eli Lilly says weight loss drug shows promise as treatment for fatty liver disease
12:06pm, Tuesday, 06'th Feb 2024
The results add to a long list of potential health benefits of tirzepatide besides helping patients shed significant pounds and regulate blood sugar.
Eli Lilly (LLY) Q4 Earnings Beat, Mounjaro, Zepbound Drive Sales
11:51am, Tuesday, 06'th Feb 2024
Eli Lilly (LLY) beats fourth-quarter estimates for earnings as well as sales. The company issues an upbeat guidance for 2024.
Earnings, Fed Speakers Dominate Activity; Lilly Beats, Spotify Misses
11:46am, Tuesday, 06'th Feb 2024
Investors of Lilly (LLY) are responding to the eye-opening efficacy of obesity drugs Mounjaro and Zepbound.
Why Eli Lilly Stock Jumped as Much as 5.1% Today Then Gave Up Its Gains
11:41am, Tuesday, 06'th Feb 2024
Eli Lilly handily beat Wall Street estimates with its Q4 results. The midpoint of the company's full-year 2024 revenue guidance range also topped the average analysts' estimate.
Why Eli Lilly Deserves to Unseat Tesla Among the Magnificent 7
11:29am, Tuesday, 06'th Feb 2024
The pharmaceutical company's market cap has surpassed Tesla's, thanks to the rapid growth of its GLP-1 business.
Eli Lilly weight loss drugs are 'mega-growth assets' BMO's Evan Seigerman says
11:20am, Tuesday, 06'th Feb 2024
Eli Lilly (LLY) shares surged Tuesday morning, after the company reported strong fourth-quarter results driven by high demand for weight loss drug Zepbound and diabetes treatment Mounjaro. Evan Seiger
Eli Lilly hits record high: Here's what investors need to know
11:09am, Tuesday, 06'th Feb 2024
Jared Holz, Mizuho Securities healthcare strategist, joins 'Squawk on the Street' to discuss why supply imbalances could boost Eli Lilly's future earnings reports, if clients are asking about the comp
Eli Lilly buoyed by demand for new weight loss drug
10:46am, Tuesday, 06'th Feb 2024
Pharma giant Eli Lilly and Co said expects revenues to grow by 18% in 2024 to more than $40 billion with the surge is attributed to the growing demand for its diabetes and obesity treatments, Mounjar
